{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=In+Expansion%3A+Melanoma%2C+Non-small+Cell+Lung+Cancer&page=3",
    "query": {
      "condition": "In Expansion: Melanoma, Non-small Cell Lung Cancer",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=In+Expansion%3A+Melanoma%2C+Non-small+Cell+Lung+Cancer&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=In+Expansion%3A+Melanoma%2C+Non-small+Cell+Lung+Cancer&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:47:29.810Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03504488",
      "title": "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Melanoma",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "CAB-ROR2-ADC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PD-1 inhibitor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioAtla, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2018-06-27",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03504488"
    },
    {
      "nct_id": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Triple Negative Breast Cancer",
        "HR+/HER2- Breast Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 557,
      "start_date": "2016-12-19",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983045"
    },
    {
      "nct_id": "NCT03361228",
      "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCB001158",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-03-01",
      "completion_date": "2019-03-30",
      "has_results": true,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03361228"
    },
    {
      "nct_id": "NCT07339176",
      "title": "Intratumoral N17350 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Solid Tumor",
        "Breast Neoplasms, Triple-Negative",
        "Squamous Cell Carcinoma of Skin",
        "Melanoma",
        "Head and Neck Neoplasms",
        "Carcinoma, Squamous Cell",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "N17350",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Onchilles Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2026-05-25",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07339176"
    },
    {
      "nct_id": "NCT03621982",
      "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer Squamous Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Pancreas Cancer",
        "Bladder Cancer",
        "Renal Cell Carcinoma",
        "Melanoma",
        "Triple-negative Breast Cancer",
        "Ovarian Cancer",
        "Colo-rectal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "ADCT-301",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ADC Therapeutics S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2018-11-09",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03621982"
    },
    {
      "nct_id": "NCT04261439",
      "title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "In Escalation: All Patients With Solid Tumors and Lymphoma",
        "In Expansion: Melanoma, Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NIZ985",
          "type": "DRUG"
        },
        {
          "name": "Spartalizumab",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-02-27",
      "completion_date": "2023-12-27",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 2,
      "location_summary": "Duarte, California • La Jolla, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04261439"
    },
    {
      "nct_id": "NCT06242470",
      "title": "A Study of MGC026 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Non Small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Bladder Cancer",
        "Sarcoma",
        "Endometrial Cancer",
        "Melanoma",
        "Castration Resistant Prostatic Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Gastro-esophageal Cancer",
        "Pancreas Cancer",
        "Clear Cell Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Platinum-resistant Ovarian Cancer",
        "Breast Cancer",
        "Ovarian Cancer",
        "Esophageal Squamous Cell Cancer (SCC)"
      ],
      "interventions": [
        {
          "name": "MGC026 Dose Escalation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MGC026 Dose for Expansion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-03-06",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06242470"
    },
    {
      "nct_id": "NCT04291079",
      "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "SRK-181",
          "type": "BIOLOGICAL"
        },
        {
          "name": "anti-PD-(L)1 antibody therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Scholar Rock, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2020-04-23",
      "completion_date": "2025-04-14",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 18,
      "location_summary": "Fullerton, California • La Jolla, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04291079"
    },
    {
      "nct_id": "NCT02817633",
      "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "TSR-022",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "TSR-042",
          "type": "DRUG"
        },
        {
          "name": "TSR-033",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 463,
      "start_date": "2016-07-08",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 64,
      "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02817633"
    },
    {
      "nct_id": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Non-small-cell Lung Cancer",
        "Melanoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07820435",
          "type": "DRUG"
        },
        {
          "name": "Sasanlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-02-08",
      "completion_date": "2025-02-13",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-10-14T11:47:29.810Z",
      "location_count": 6,
      "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06285097"
    }
  ]
}